Preparation and application of selective heat shock protein 90 inhibitor
By developing selective Hsp90α inhibitors, the lack of selectivity and toxicity of Hsp90 inhibitors in the prior art was solved, effective inhibition of Hsp90α was achieved, and the therapeutic effect on tumor cells was significantly improved.
Patent Information
- Application Number
- CN202411210517.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-30
AI Technical Summary
The existing Hsp90 inhibitors lack selectivity, resulting in toxic effects, making it difficult to distinguish different Hsp90 subtypes, limiting their effective application in the treatment of diseases such as tumors.
A series of compounds have been developed as selective Hsp90α inhibitors, and compounds with significant inhibition of Hsp90α activity were prepared through specific structural general formulas and synthetic routes for tumor treatment.
These compounds have significant inhibitory activity on Hsp90α, show anti-tumor proliferation activity, and improve the therapeutic effect on a variety of tumor cells, especially in the prevention and treatment of Hsp90α-mediated disorders, diseases or diseases. .
Smart Images

Figure CN119080665A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to a class of compounds, pharmaceutical compositions containing such compounds and methods for preparing them. The present invention also relates to the use of the compounds as selective Hsp90α inhibitors for treating diseases such as tumors. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Heat shock protein 90 (Hsp90) is one of the active molecular chaperone proteins in cells. The normal function of many signal transduction proteins depends on Hsp90. When cells undergo stress response, it can interact with proteins whose conformation changes due to environmental stimuli to ensure proper folding of proteins and prevent non-specific aggregation of proteins, thereby maintaining normal cell activity. In addition, Hsp90 is also an important buffer factor in the process of cell mutation, which can correct the misfolding of mutant proteins. When cells are in normal physiological conditions, Hsp90 is an important regulator. It is currently known that it regulates the spatial structure and mutation of about 40 proteins. All of these proteins are important regulatory proteins in the process of cell physiological and biochemical changes.
[0004] As a well-known chaperone protein, Hsp90 plays an important role in preventing protein aggregation and degrading misfolded and transient proteins. Hsp90 mainly exists as a homodimer, and each monomer consists of an N-terminal domain, an intermediate domain, and a C-terminal domain. The main isoforms of Hsp90 are cytoplasmic Hsp90α and Hsp90β, endoplasmic reticulum glucose-regulated protein 94 (Grp94), and mitochondrial TNF receptor-associated protein 1 (Trap1). Although these four isoforms have many highly conserved domains and more than 50% sequence homology, their functions are quite different. The stress-induced isoform of Hsp90, Hsp90α, is encoded by the HSP90AA1 gene, and the constitutive Hsp90β is encoded by the HSP90AB1 gene. Hsp90 is involved in protein folding, stabilization, and maturation in normal and cancer cells. Both Hsp90α and Hsp90β are highly associated with cancer-related signaling pathways. Among the four analogs, the mitochondrial chaperone Trap1 has anti-apoptotic and antioxidant properties and can regulate reactive oxygen species (ROS)-mediated lethal stress and chaperone denaturation to protect mitochondrial integrity. A recently published article confirmed that Grp94 can promote cell migration and affect intracellular trafficking. Hsp90 has hundreds of clients, including various kinases and hormone receptors. A variety of oncoproteins rely on Hsp90 to fold their conformations. Overexpression of Hsp90 is highly associated with many different pathological conditions, especially tumor progression. In addition, some cancer cells are also hypersensitive to the inhibition of Hsp90. Hsp90 inhibitors can also be used to treat other medical diseases, such as infectious diseases, inflammation, neurodegenerative diseases, etc.
[0005] So far, about 20 compounds have entered clinical trials, but almost none have been approved by the US Food and Drug Administration (FDA). These failures may be due to the fact that almost all current clinical candidate drugs are pan-Hsp90 inhibitors. They can cause many toxic effects, such as hepatotoxicity, ocular toxicity, and heat shock response. Lack of selectivity is an important factor causing the inevitable toxicity of Hsp90 inhibitors. The development of isoform-specific inhibitors is limited by our insufficient understanding of the biology of Hsp90. Due to the high sequence identity of different Hsp90 isoforms, especially Hsp90α and Hsp90β isoforms, it is difficult for inhibitors to distinguish between different Hsp90 isoforms. Summary of the invention
[0006] In view of the problems existing in the prior art, the present invention provides the preparation and application of selective heat shock protein 90 inhibitors. Specifically, the present invention obtains a series of compounds, which can be used as Hsp90α inhibitors, and further can be used for the treatment of diseases such as tumors. Based on the above research results, the present invention is completed.
[0007] Specifically, the present invention relates to the following technical solutions:
[0008] The first aspect of the present invention provides a compound having the general structural formula shown in Formula I below or a pharmaceutically acceptable salt, solvate or hydrate thereof:
[0009]
[0010] in:
[0011] R 1 is selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, halogen, cyano, hydroxy, alkoxy, nitro, amino, monoalkylamino, and dialkylamino;
[0012] R 2 Selected from -C(O)NR 3 R 4 、-S(O)NR 3 R 4 and -S(O) 2 NR 3 R 4 ;
[0013] R 3 and R 4 each independently selected from H, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl and substituted alkyl, wherein the cycloalkyl and heterocyclyl are optionally and independently substituted with substituents selected from alkyl, hydroxy, halogen and alkoxy, and wherein the substituents of the substituted alkyl are selected from hydroxy, amino, monoalkylamino, dialkylamino, alkylcarbonylamino, cycloalkyl, cycloalkylcarbonyl, aryl, heteroaryl, alkoxy, heterocyclyl and heterocyclylcarbonyl, the cycloalkyl and heterocyclyl in the substituents of the substituted alkyl are optionally and independently substituted with substituents selected from alkyl, hydroxy and alkoxy, and the aryl or heteroaryl in the substituents of the substituted alkyl are optionally and independently substituted with substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, sulfamoyl, alkylsulfamoyl, alkylcarbonyl and halogen; or
[0014] R 3 and R 4 Together with the N atom to which they are attached they form a heterocyclyl optionally containing an additional heteroatom, wherein the heterocyclyl is optionally and independently substituted with 1, 2 or 3 substituents selected from alkyl, hydroxy, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, heterocyclyl, aryl, arylalkyl, heteroaryl, alkoxyalkyl, alkylcarbonyl, alkylcarbonyloxy, aminoalkylcarbonyloxy, oxo, halogen, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, alkylcarbonylaminoalkyl, alkylcarbonylalkylaminoalkyl, amino, monoalkylamino and dialkylamino.
[0015] In one embodiment of the present invention, the compound of formula I has formula IA:
[0016]
[0017] Where R 1 and R 2 As defined in Formula I.
[0018] In one embodiment of the present invention, there is provided a compound of formula I or IA, wherein:
[0019] R 1 Selected from H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, hydroxyl, C 1-6 Alkoxy, nitro, amino, single C 1-6 Alkylamino and di-C 1-6 Alkylamino;
[0020] R 2 Selected from -C(O)NR 5 R 6 and -S(O) 2 NR 5 R 6 ;
[0021] R 3 and R 4 Each independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, 5-10 membered heteroaryl and substituted C 1-6 Alkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl, halogen and C 1-6 Alkoxy is substituted with a substituent, and wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 The alkoxy group is substituted with a substituent, the substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or
[0022] R 3 and R 4 Together with the N atom to which they are attached, they form a 3-8 membered heterocyclic group optionally containing 1, 2 or 3 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
[0023] In one embodiment of the present invention, there is provided a compound of formula I or IA, wherein:
[0024] R 1 Selected from H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, halogen, hydroxyl and C 1-6 Alkoxy;
[0025] R 2 -C(O)NR 5 R 6 ;
[0026] R 3 and R 4 Each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl and substituted C 1-6 Alkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 Alkoxy is substituted with a substituent, and wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or
[0027] R 3 and R 4 Together with the N atom to which they are attached, they form a 3-8 membered heterocyclic group optionally containing 1 or 2 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
[0028] In one embodiment of the present invention, there is provided a compound of formula I or IA, wherein:
[0029] R 1 Selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl;
[0030] R 2 -C(O)NR 5 R 6 ;
[0031] R 3 and R 4 Each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl and substituted C 1-6 Alkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 Alkoxy is substituted with a substituent, and wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or
[0032] R 3 and R 4 Together with the N atom to which they are attached, they form a 3-8 membered heterocyclic group optionally containing 1 or 2 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
[0033] In one embodiment, R 1 Selected from H, C1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, cyano, hydroxyl, C 1-6 Alkoxy, nitro, amino, single C 1-6 Alkylamino and di-C 1-6 Alkylamino.
[0034] In one embodiment, R 1 Selected from H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, halogen, cyano, hydroxyl, C 1-6 Alkoxy and amino.
[0035] In another embodiment, R 1 Selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, cyano and C 1-6 Alkoxy.
[0036] In another embodiment, R 1 Selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 3-6 Cycloalkyl and cyano.
[0037] In another preferred embodiment, R 1 Selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, -CF 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyano.
[0038] In another more preferred embodiment, R 1 Selected from n-propyl, isopropyl, tert-butyl, -CF 3 , cyclopropyl, cyclobutyl and cyano.
[0039] In another most preferred embodiment, R 1 Selected from isopropyl, -CF 3 , cyclopropyl and cyano.
[0040] In one embodiment, R 2 Selected from -C(O)NR 5 R 6 and -S(O) 2 NR 5 R 6 .
[0041] In one embodiment, R2 -C(O)NR 5 R 6 .
[0042] In one embodiment, R 3 Selected from H, C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0043] In one embodiment, R 3 Selected from H, C 1-6 Alkyl and C 1-6 Alkoxy C 1-6 alkyl.
[0044] In one embodiment, R 3 Selected from H, C 1-4 Alkyl and C 1-4 Alkoxy C 1-4 alkyl.
[0045] In one embodiment, R 3 is selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl and C 1-4 Alkoxy C 1-4 alkyl.
[0046] In one embodiment, R 3 is selected from the group consisting of H, methyl, ethyl, n-propyl, n-butyl, methoxyethyl, methoxymethyl, ethoxyethyl and ethoxymethyl.
[0047] In one embodiment, R 3 Selected from H, methyl, ethyl, n-propyl, n-butyl and methoxyethyl.
[0048] In one embodiment, R 4 Selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, 5-10 membered heteroaryl and substituted C 1-6 Alkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl, halogen and C 1-6 Alkoxy is substituted with a substituent, and wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 The alkoxy group is substituted with a substituent, the substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or R 3 and R 4 Together with the N atom to which they are attached, they form a 3-8 membered heterocyclic group optionally containing 1, 2 or 3 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
[0049] In one embodiment, R 4 Selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl and substituted C 1-6 Alkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl, halogen and C 1-6 Alkoxy is substituted with a substituent, and wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 The alkoxy substituent is substituted with the C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or R 3 and R 4 Together with the N atom to which they are attached, they form a 3-8 membered heterocyclic group optionally containing 1, 2 or 3 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
[0050] In a preferred embodiment, R 4 Selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl and substituted C 1-6 Alkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6Alkylcarbonyl, halogen substituents; or R 3 and R 4 Together with the N atom to which they are attached, they form a 3-8 membered heterocyclic group optionally containing 1 or 2 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
[0051] The present invention also provides specific compounds of Formula I shown in Table 1 below, or pharmaceutically acceptable salts, solvates or hydrates thereof.
[0052] Table 1: Some specific compounds of the present invention
[0053]
[0054]
[0055]
[0056]
[0057]
[0058] The term "pharmaceutically acceptable salt" in the present invention refers to a salt of the compound of the present invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Such salts include: acid addition salts formed with inorganic acids or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, camphorsulfonic acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, etc.; or salts formed when the acidic protons present on the parent compound are replaced by metal ions, such as alkali metal ions or alkaline earth metal ions; or coordination compounds formed with organic bases, such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc.
[0059] The term "solvate" in the present invention refers to a substance formed by combining the compounds of the present invention with a pharmaceutically acceptable solvent. Pharmaceutically acceptable solvents include, but are not limited to, water, ethanol, acetic acid, etc. Solvates include stoichiometric solvates and non-stoichiometric solvates, preferably hydrates. The compounds of the present invention can be crystallized or recrystallized with water or various organic solvents, in which case various solvates may be formed. The solvates of the present invention may be hydrates.
[0060] The subject of the present invention refers to an animal that has been the object of treatment, observation or experiment, preferably a mammal, and most preferably a human.
[0061] Those skilled in the art will appreciate that the compounds of the present invention exist in isomers, such as stereoisomers (including enantiomers and diastereomers) and cis-trans isomers. Therefore, when referring to the compounds of the present invention in this specification, the compounds of the present invention include the compounds of Formula I and pharmaceutically acceptable salts, isomers, solvates and hydrates thereof. More specifically, the compounds of the present invention include single enantiomers, mixtures of enantiomers or mixtures of diastereomers thereof.
[0062] Pharmaceutical composition
[0063] In one embodiment, the present invention provides a pharmaceutical composition. The pharmaceutical composition provided by the present invention comprises a compound of formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof; and a pharmaceutically acceptable auxiliary material, medium, carrier, diluent or excipient.
[0064] Suitable excipients are well known to those skilled in the art, and the present invention provides non-limiting examples of suitable excipients. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors known to those skilled in the art, including, but not limited to, the method of administration. For example, oral dosage forms such as tablets may contain excipients that are not suitable for parenteral dosage forms. The suitability of a specific excipient also depends on the specific active ingredient in the dosage form. For example, the decomposition of some active ingredients may be accelerated by certain excipients such as lactose or when in contact with water. Active ingredients containing primary and secondary amines are particularly sensitive to this accelerated decomposition. Therefore, the pharmaceutical composition or dosage form provided by the present invention, if any, contains a small amount of lactose other mono- or di-saccharides. As used in the present invention, the term "lactose-free" means that, if any, the amount of lactose present is substantially insufficient to increase the degradation rate of the active ingredient. In one embodiment, a lactose-free composition comprises an active ingredient, a binder / filler, and a lubricant provided by the present invention. In another embodiment, a lactose-free dosage form comprises an active ingredient, microcrystalline cellulose, pregelatinized starch, and magnesium stearate.
[0065] The compound provided by the present invention can be used alone, or in combination with one or more other compounds provided by the present invention. The pharmaceutical composition comprises a compound of formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof, and the pharmaceutical composition can be formulated into different dosage forms suitable for oral, parenteral and topical administration. The pharmaceutical composition can also be formulated into a modified release dosage form, including delayed, extended, prolonged, sustained, pulsed, controlled, accelerated, rapid, directional, programmed release, and intragastric retention dosage form. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see, Remington: Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Modified-Release Drug Delivery Technology, 2nd ed.; Rathbone et al., Eds.; Marcel Dekker, Inc.: New York, NY, 2008).
[0066] In one embodiment, the pharmaceutical composition is provided in a dosage form for oral administration, the dosage form comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
[0067] In another embodiment, the pharmaceutical composition is provided in a dosage form for parenteral administration, the dosage form comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
[0068] In yet another embodiment, the pharmaceutical composition is provided in a dosage form for topical administration, the dosage form comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
[0069] Pharmaceutical compositions provided by the present invention can be provided in single dose form or multiple dose form. As used in the present invention, single dose form refers to physically discrete units suitable for application to human and animal subjects, and is packaged separately, as is known in the art. Each unit dose contains a predetermined amount of active ingredients sufficient to produce the therapeutic effect required, and the pharmaceutical carrier or excipient required. Examples of single dose forms include ampoules, syringes, and separately packaged tablets and capsules. For example, a 100 mg unit dose contains about 100 mg of active ingredients in a packaged tablet or capsule. Single dose forms can be used in part or multiple times. Multiple dose forms are multiple identical single dose forms packaged in a single container, used in separated single dose forms. Examples of multiple dose forms include bottles of glass bottles, tablets or capsules, or pint or gallon bottles.
[0070] Pharmaceutical composition provided by the invention can be used once, or repeatedly at certain intervals. It should be understood that accurate dosage and treatment duration can change with age, body weight and condition of the patient to be treated, and can be determined empirically using known test protocols or from in vivo or in vitro tests or diagnostic data extrapolation. It should also be understood that for any specific individual, specific dosage regimen should be adjusted over time according to the needs of this individual and the professional judgment of the people who use or instruct the formula to use.
[0071] How to use
[0072] In one embodiment, the present invention provides a method for treating, preventing or ameliorating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof.
[0073] In another embodiment, the present invention provides a method for treating, preventing or ameliorating one or more symptoms of a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof.
[0074] In another embodiment, the present invention provides a method for treating, preventing or ameliorating a subject's Hsp90 (particularly Hsp90α)-mediated disorder, disease or condition, the method comprising administering to the subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof. In one embodiment, the Hsp90α-mediated disorder, disease or condition is a proliferative disease.
[0075] In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human.
[0076] In one embodiment, the proliferative disease is a tumor. In another embodiment, the proliferative disease is a solid tumor. In another embodiment, the proliferative disease is a cancer. In certain embodiments, the proliferative disease is a drug-resistant cancer. In certain embodiments, the proliferative disease is a metastatic cancer.
[0077] In one embodiment, cancers that can be treated using the methods provided herein include, but are not limited to, bladder cancer, breast cancer, cervical cancer, colon cancer (e.g., colorectal cancer), esophageal cancer, head and neck cancer, liver cancer, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, sarcoma (e.g., osteosarcoma), skin cancer (e.g., squamous cell carcinoma), gastric cancer, testicular cancer, thyroid cancer, and uterine cancer.
[0078] In one embodiment, the present invention provides a method of inhibiting cell growth, comprising contacting the cell with a compound of formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof.
[0079] In certain embodiments, the cell is a mammalian cell. In certain embodiments, the cell is a human cell. In certain embodiments, the cell is a tumor cell. In certain embodiments, the cell is a mammalian tumor cell. In certain embodiments, the cell is a human tumor cell. In certain embodiments, the cell is a cancer cell. In certain embodiments, the cell is a mammalian cancer cell. In certain embodiments, the cell is a human cancer cell.
[0080] In certain embodiments, cancer cells that can be treated using the methods provided herein include, but are not limited to, cells of bladder cancer, breast cancer, cervical cancer, colon cancer (e.g., colorectal cancer), esophageal cancer, head and neck cancer, liver cancer, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, sarcoma (e.g., osteosarcoma), skin cancer (e.g., squamous cell carcinoma), gastric cancer, testicular cancer, thyroid cancer, and uterine cancer.
[0081] In one embodiment, the cell is a cell of bladder cancer, squamous cell carcinoma, head and neck cancer, colorectal cancer, esophageal cancer, gastric cancer, gynecological cancer, pancreatic cancer, rectal cancer, breast cancer, prostate cancer, vulvar cancer, skin cancer, brain cancer, genitourinary tract cancer, cancer of the lymphatic system, stomach cancer, laryngeal cancer, or lung cancer.
[0082] In certain embodiments, the cancer cell is a metastatic cancer cell, including but not limited to cells of bladder cancer, breast cancer, cervical cancer, colon cancer (e.g., colorectal cancer), esophageal cancer, head and neck cancer, liver cancer, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, sarcoma (e.g., osteosarcoma), skin cancer (e.g., squamous cell carcinoma), gastric cancer, testicular cancer, thyroid cancer, and uterine cancer.
[0083] Inhibition of cell growth can be measured, for example, by counting the number of cells contacted with the compound of interest, comparing to otherwise identical cells that were not contacted with the compound, or measuring the size of a tumor containing the cells. Cell number and cell size can be readily assessed using any method known in the art (e.g., trypan blue exclusion and cell counting, measuring the amount of nascent DNA incorporated into the cell). 3 H-thymidine).
[0084] In one embodiment, the present invention provides a method for inhibiting the activity of Hsp90 (especially Hsp90α) enzyme, which comprises contacting the Hsp90 enzyme with a compound of formula I provided by the present invention or a pharmaceutically acceptable salt, solvate or hydrate thereof.
[0085] Beneficial technical effects of one or more of the above technical solutions:
[0086] The compounds designed by the above technical scheme have significant inhibitory activity on Hsp90 (especially Hsp90α), and experiments have shown that they have anti-tumor proliferation activity on a variety of tumor cells. Therefore, they can be used for the prevention and treatment of Hsp90 (especially Hsp90α)-mediated disorders, diseases or symptoms, especially tumor-related diseases, and therefore have good practical application value. DETAILED DESCRIPTION
[0087] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0088] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.
[0089] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out under conventional conditions or under conditions recommended by the sales company; the materials and reagents used in the examples, unless otherwise specified, can be purchased through commercial channels.
[0090] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0091] Example 1
[0092] The intermediate H used to prepare the compound of formula I of the present invention is synthesized, for example, by the following Scheme 1:
[0093]
[0094]
[0095] Solution 1
[0096] Compound B
[0097] Compound A (6.1 g, 41.2 mmol) was dissolved in 150 mL of methanol and cooled to 0°C by ice bath, followed by dropwise addition of 5.7 mL (78.5 mmol) of thionyl chloride. After addition, the mixture was stirred at room temperature overnight. After TLC monitoring, the solvent was removed by rotary evaporation to obtain a white solid, namely compound B (7.3 g, 98%). LCMS (ESI): calculated value C 14 H 16 NO 4 [M+H] + 182.06, measured value 182.2.
[0098] Compound C
[0099] Compound B (7.3 g, 40.2 mmol) and DMAP (200 mg, 1.64 mmol) were dissolved in a mixture of anhydrous dichloromethane (120 mL) and triethylamine (30.7 mL, 221 mmol). After all the solution was dissolved, the mixture was placed in an ice bath for half an hour. Benzoyl chloride (5.2 mL, 44.1) was added dropwise at 0°C. After the addition, the mixture was naturally heated to room temperature and stirred overnight. After the reaction was completed as monitored by TLC, 20 mL of saturated saline was added to the reaction system. The mixture was extracted with dichloromethane, the organic phases were combined, dried with anhydrous sodium sulfate, filtered, and the solvent was removed on a rotary evaporator. The mixture was recrystallized from dichloromethane to obtain a light yellow solid, which was compound C (7.4 g, 74%). LCMS (ESI): calculated value C 6 H 13 ClNO 3 [M+H] + 262.11, measured value 262.3.
[0100] Compound D
[0101] Compound C (7.4 g, 29.7 mmol) was dissolved in a mixture of dichloromethane (100 mL) and triethylamine (12.5 mL), replaced with nitrogen, and cooled to 0°C using an ice-water bath. 3.5 mL (44.9 mmol) of methylsulfonyl chloride was added dropwise. After the addition, the mixture was stirred at room temperature overnight. After the reaction was completed as monitored by TLC, 20 mL of saturated brine was added to the reaction system. The mixture was extracted with dichloromethane, the organic phases were combined, dried with anhydrous sodium sulfate, and purified using a silica gel column to obtain a light yellow solid, which was compound D (8.4 g, 87%). LCMS (ESI): calculated value C 14 H 18 NO 6 S[M+H] + 328.09, measured value 328.2.
[0102] Compound E
[0103] Dissolve compound D in 50 mL of tetrahydrofuran, then place it in a 20-25 °C water bath and add LiOH·H 2 O (2.6 g, 61.9 mmol) and 50 mL of water were mixed evenly and stirred for 20 min. After the hydrolysis was complete, tetrahydrofuran was removed on a rotary evaporator. The remaining water layer was acidified to a pH of about 2 with concentrated hydrochloric acid, sodium chloride was added to saturate it, and extracted with dichloromethane. The organic phase was collected and dried over anhydrous sodium sulfate. After filtration, the solvent was removed on a rotary evaporator to obtain a white solid E (7.8 g, 100%). 1 H NMR (400 MHz, CDCl 3)δppm 7.54-7.33 (m, 5H), 5.24-5.23 (m, 1H), 4.95-4.92 (m, 1H), 3.89-3.88 (m, 1H), 3.04 (s, 3H), 2.67-2.62 (m, 2H). LCMS (ESI): calculated value C 13 H 16 NO 6 S[M+H] + 314.07, measured value 314.3.
[0104] Compound F
[0105] Compound E (7.8 g, 24.9 mmol) was dissolved in 150 mL of benzene, and the reaction system was placed in a constant temperature water bath at 10°C, and anhydrous aluminum chloride (11.9 g, 89.3 mmol) was added to the reaction bottle, and stirred overnight. After the reaction was completed by TLC monitoring, cold water was added to quench the reaction, the benzene layer was collected, and the aqueous layer was saturated with sodium chloride and extracted with dichloromethane, and the organic phase was collected, combined with the benzene layer, dried with anhydrous sodium sulfate, and then filtered, the solvent was removed on a rotary evaporator, and purified with a silica gel column to obtain a white solid F (4.4 g, yield 60%). 1 H NMR (200 MHz, CDCl 3 )δppm 7.63 (d, J = 3.4 Hz, 2H), 7.49-7.47 (m, 2H), 7.38-7.36 (m, 2H), 7.26-7.24 (m, 2H), 5.01 (d, J = 3.8 Hz, 1H), 4.04-4.02 (m, 1H), 3.71-3.63 (m, 2H), 2.78-2.77 (m, 1H), 2.53-2.51 (m, 1H). LCMS (ESI): calculated value C 18 H 18 NO 3 [M+H] + 296.13, measured value 296.3.
[0106] Compound G
[0107] Compound F (3.2 g, 10.9 mmol) was added to 120 mL of 6 M hydrochloric acid solution and heated to reflux. When the compound was completely dissolved, the reaction was continued for 1 h. After the reaction was completed, the heating was stopped and the mixture was cooled to room temperature. A large amount of white solid precipitated and filtered. TLC showed that the white solid was benzoic acid. The filtrate was extracted with dichloromethane 3-5 times, and then the aqueous solution was removed from the solvent on a rotary evaporator to obtain a white solid. The white solid was dissolved in 5 mL of water and recrystallized to obtain white crystals G (1.6 g, yield 70%). LCMS (ESI): calculated value C 11 H 15ClNO 2 [M+H] + 228.08, measured value 228.2.
[0108] Compound H
[0109] Compound G (6.8 g, 20 mmol) was dissolved in 80 mL of methanol and cooled to 0°C in an ice bath, followed by dropwise addition of 2.8 mL (38 mmol) of thionyl chloride. After addition, the mixture was stirred overnight at room temperature. After TLC monitoring of the reaction was complete, the solvent was removed by rotary evaporation to obtain a white solid, namely compound H (4.3 g). LCMS (ESI): calculated value C 12 H 17 ClNO 2 [M+H] + 242.09, measured value 242.3.
[0110] Example 2
[0111] The compounds of formula I of the present invention are synthesized by, for example, the following scheme 2, that is, compounds 1-36 corresponding to Table 1, wherein R 1 For H, R 2 is cyclopropyl, R 4 For phenyl:
[0112]
[0113]
[0114] Solution 2
[0115] Methyl 5-bromo-2,4-dihydroxybenzoate (2-1a)
[0116] Dissolve 8.4 g (50 mmol) of methyl 2,4-dihydroxybenzoate in 40 mL of chloroform and cool to 0°C. Dissolve 2.56 mL (50 mmol) of bromine in 20 mL of chloroform, mix well and drip into the above system. After dripping, naturally warm the reaction system to room temperature and stir for 4 hours. After TLC detection, add 30 mL of saturated NaHCO 3 , washed with 30 mL of water, and after separation, the organic phase was washed with anhydrous Na 2 SO 4 Drying, followed by filtration and removal of the solvent on a rotary evaporator afforded a white solid (11.86 g, 96% yield). 1 H NMR (600 MHz, CDCl 3 )δppm 10.86 (s, 1H), 7.97 (s, 1H), 6.63 (s, 1H), 6.06 (s, 1H), 3.94 (s, 3H); LCMS (ESI): calculated value C 8H 7 B O 4 [MH] - 244.94, measured value 245.2.
[0117] Methyl 5-bromo-2,4-bis(methoxymethoxy)benzoate (2-1b)
[0118] 0.49 g (2 mmol) of methyl 5-bromo-2,4-dihydroxybenzoate was dissolved in 15 mL of freshly distilled acetonitrile, and then 2.09 mL (12 mmol, 1.55 g) of DIEA and 0.65 mL (8.6 mmol, 0.69 g) of MOMCl were added in sequence. The mixture was stirred at room temperature for 12 h. After the reaction was complete, 10 mL of water was added, and the mixture was extracted with EA. The organic phases were combined, washed with water, and then washed with anhydrous Na 2 SO 4 After drying, filtering and removing the solvent on a rotary evaporator, a yellow solid (75%) was obtained. 1 H NMR (400 MHz, CDCl 3 )δppm 8.05 (s, 1H), 7.01 (s, 1H), 5.28 (s, 2H), 5.24 (s, 2H), 3.87 (s, 3H), 3.52 (s, 3H), 3.52 (s, 3H); LCMS (ESI): calculated value C 12 H 15 BrNaO 6 [M+Na] + 356.99, measured value 357.3.
[0119] 5-Cyclopropyl-2,4-bis(methoxymethoxy)benzoic acid methyl ester (2-1c)
[0120] Mix 5.5 mL of toluene and water (Tol:H 2 O=10:1) and then added 335mg (1mmol) of methyl 5-bromo-2,4-di(methoxymethoxy)benzoate, 128mg (1.5mmol) of cyclopropylboric acid, 58mg (0.05mmol) of tetrakis(triphenylphosphine)palladium, 483mg (3.5mmol) of K 2 CO 3 , Ar gas replacement for 5 minutes, heating to 110 ° C, cooling to room temperature after 5 hours, adding 10 mL of water, EA extraction, combining the organic phases and washing with saturated brine, 2 SO 4 Drying, followed by filtration, removal of the solvent on a rotary evaporator and purification by silica gel column chromatography (0%-20% EA / Hex) gave a yellow oil (0.26 g, 88.4%). 1 H NMR (300 MHz, CDCl 3)δppm 7.39 (s, 1H), 6.70 (s, 1H), 5.25 (d, 2H, J = 4.8 Hz), 5.20 (d, 2H, J = 5.1 Hz), 3.85 (s, 3H), 3.52 (s, 3H), 3.51 (s, 3H), 2.10-2.00 (m, 1H), 0.93-0.87 (m, 2H), 0.67-0.61 (m, 2H); LCMS (ESI): calculated value C 15 H 20 NaO 6 [M+Na] + 319.12, measured value 319.3.
[0121] 5-Cyclopropyl-2,4-di(methoxymethoxy)benzoic acid (2-1d)
[0122] 0.4 g (1.3 mmol) of methyl 5-cyclopropyl-2,4-di(methoxymethoxy)benzoate was dissolved in 20 mL of MeOH, 11 mL of 2M LiOH was added, and the mixture was stirred at room temperature for 24 h. After the reaction was completed, 20 mL of DCM was added, and the aqueous phase was separated and the pH value was adjusted to 3-4 with 0.87 M HAc, and extracted with EA. After the organic phases were combined, they were washed with saturated brine until neutral, and anhydrous Na 2 SO 4 After drying and filtering, the solvent was removed on a rotary evaporator to obtain a white solid (0.28 g, yield 73.7%). 1 H NMR (300 MHz, CDCl 3 )δppm 7.66 (s, 1H), 6.97 (s, 1H), 5.38 (s, 2H), 5.29 (s, 2H), 3.55 (s, 3H), 3.52 (s, 3H), 2.11-2.01 (m, 1H), 0.95-0.88 (m, 2H), 0.71-0.65 (m, 2H). LCMS (ESI): calculated value C 14 H 18 NaO 6 [M+Na] + 305.10, measured value 305.1.
[0123] (2R,4R)-1-(5-cyclopropyl-2,4-di(methoxymethoxy)benzoyl)-4-phenylpyrrolidine-2-carboxylic acid methyl ester (2-1e)
[0124] 28 mg (0.1 mmol) of the compound 5-cyclopropyl-2,4-di(methoxymethoxy)benzoic acid, 38 mg (0.1 mmol) of HATU and 0.08 ml of DIEA (0.5 mmol, 63 mg) were dissolved in 5 mL of DCM, and then 24 mg (0.1 mmol) of cis-4-phenyl-D-proline methyl ester hydrochloride (H) was added and stirred at room temperature overnight. After TLC detection, the reaction was complete, and then washed with 5 mL of sodium bicarbonate and 5 mL of saturated brine. After drying with anhydrous sodium sulfate, a colorless oil (0-30% EA / Hex) was obtained by column chromatography. 1 H NMR (300 MHz, CDCl 3 )δ ppm 7.34-7.16 (m, 5H), 6.87-6.84 (m, 2H), 5.21 (s, 2H), 5.13 (s, 2H), 3.82 (s, 3H), 3.49 (s, 3H), 3.45 (s, 3H), 2.80 (s, 2H), 2.45-2.37 (m, 2H), 0.91-0.86 (m, 5H), 0.64-0.56 (m, 2H); LCMS (ESI): calculated value C 26 H 32 NO 7 [M+H] + 470.22, measured value 470.6.
[0125] (2R,4R)-1-(5-cyclopropyl-2,4-di(methoxymethoxy)benzoyl)-4-phenylpyrrolidine-2-carboxylic acid (2-1f)
[0126] 0.4 g of (2R, 4R)-1-(5-cyclopropyl-2,4-di(methoxymethoxy)benzoyl)-4-phenylpyrrolidine-2-carboxylic acid methyl ester was dissolved in 10 mL of MeOH, and 5 mL of 2M LiOH was added. The mixture was stirred at room temperature for 24 h. After the reaction was completed, 10 mL of DCM was added. After separation, the pH value of the aqueous phase was adjusted to 3-4 with 0.87 M HAc, and extracted with EA. After the organic phases were combined, they were washed with saturated brine until neutral, and washed with anhydrous Na 2 SO 4 Drying, followed by filtration, and removal of the solvent on a rotary evaporator afforded a white solid (yield 86.7%). 1H NMR (300 MHz, DMSO) δ ppm 12.65 (br s, 1H), 7.35-7.21 (m, 5H), 6.83 (s, 1H), 6.84 (m, 2H), 6.62 (s, 1H), 5.24 (s, 2H), 5.12 (s, 2H), 3.69-3.63 (m, 1H), 3.56-3.51 (m, 2H), 3.48 (s, 3H), 3.39 (s, 3H), 2.34-2.29 (m, 2H), 2.05-1.99 (m, 1H), 0.88-0.83 (m, 2H), 0.56-0.52 (m, 2H), LCMS (ESI): calculated value C 25 H 28 NO 7 [MH] - 454.50, measured value 454.5.
[0127] Compound 1-36
[0128] Compound 1f (100 mg, 0.22 mmol), R 5 R 6 NH (0.22mmol) and triethylamine (0.33mmol) were dissolved in DCM (2mL), and HOBT (69.96mg, 0.33mmol) and EDC (63.26mg, 0.33mmol) were added, and the reaction was stirred at room temperature overnight. The reaction solution was added to 20mL DCM and washed three times with water (20mL×3), the organic layer was separated and dried, and the crude product of compound 2-1-36g was obtained by spin drying. The crude product of compound 2-1-36g was dissolved in MeOH (2mL), and the corresponding EA.HCl was added, and the mixture was stirred at room temperature for about 30min, the solvent was removed by spin drying, and solid 1-36 was obtained by HPLC preparation (compound data is shown in the table below).
[0129]
[0130]
[0131]
[0132]
[0133]
[0134] Example 3
[0135] Similar to the above Example 2, the compounds of formula I of the present invention, i.e. compounds 37-90 in Table 1, were synthesized by, for example, the following Scheme 3, wherein R 1 For H, R 2 is isopropyl, R4 For phenyl:
[0136]
[0137] Solution 3
[0138] 5-Acetyl-2,4-dihydroxybenzoic acid methyl ester (3-1a)
[0139] Acetic anhydride (3.06 g, 30 mmol) and methyl 2,4-dihydroxybenzoate (5.04 g, 30 mmol) were added to 7.6 ml of boron trifluoride ether solution, and the reaction solution was refluxed for 3 h. After the reaction was completed, it was cooled to room temperature, 80 mL of water was added, and the reaction system was stirred at room temperature for 30 min. The yellow solid was filtered to obtain a yellow solid, which was dried under reduced pressure. The dried yellow solid was dissolved in DCM, the organic phase was washed with water, and anhydrous Na 2 SO 4 The organic phase was dried and concentrated under reduced pressure to give a bright yellow solid (2.0 g).
[0140] MS: [M+H] + 211.
[0141] 5-Acetyl-2,4-di(benzyloxy)benzoic acid methyl ester (3-1b)
[0142] Dissolve 5-acetyl-2,4-dihydroxybenzoic acid methyl ester (2g, 9.5mmol) in 40mL acetonitrile, add potassium carbonate (3.9g, 28.5mmol), then add benzyl bromide (4.0g, 23.75mmol) and reflux the reaction system for 3h. After the reaction is completed, concentrate under reduced pressure, then add water and dichloromethane to the filter residue, separate the organic phase, and add anhydrous Na 2 SO 4 After drying and concentration under reduced pressure, a colorless solid 3-1b (2.2 g) was obtained.
[0143] MS: [M+H] + 391.
[0144] 2,4-Di-benzyloxy-5-isopropenyl-benzoic acid methyl ester (3-1c)
[0145] Under nitrogen atmosphere, add methyl triphenylphosphine bromide (1.96g, 5.5mmol) to 20mL anhydrous THF and cool to 0℃. Add BuLi (1.6M, in hexane, 3.5mL, 5.5mmol) dropwise to the above solution. After the addition is complete, stir and react at 0℃ for 30min. Dissolve 5-acetyl-2,4-di(benzyloxy)benzoic acid methyl ester (1.95g, 5.0mmol) in THF (20mL), add the liquid dropwise to the above solution, and stir and react at room temperature for 16h. After the reaction is completed, add 10mL of methanol and concentrate under reduced pressure. Add water and dichloromethane to the filter residue, separate the organic phase, and anhydrous Na 2 SO 4 After drying and concentration under reduced pressure, the crude product was purified by silica gel column chromatography (0%-7% EA / PE) to give a colorless solid 4-1c (0.5 g).
[0146] MS: [M+H] + 389.
[0147] 5-Isopropyl-2,4-dihydroxybenzoic acid methyl ester (3-1d)
[0148] In a hydrogen atmosphere, 2,4-di-benzyloxy-5-isopropenyl-benzoic acid methyl ester (3.88 g, 10.0 mmol) was dissolved in ethanol (30 mL), and 10% Pd / C (350 mg) was added. The reaction system was stirred at room temperature for 1 h. After 1 h, ethanol (20 mL) was added and stirred at room temperature for 16 h. After the reaction was completed, the residue was filtered and washed with ethanol (3×20 mL). The organic phase was combined and concentrated under reduced pressure to obtain a colorless solid 3-1d (2.0 g).
[0149] MS: [M+H] + 221.
[0150] 5-Isopropyl-2,4-di(methoxymethoxy)benzoic acid methyl ester (3-1e)
[0151] 0.42 g (2 mmol) of 5-isopropyl-2,4-dihydroxybenzoic acid methyl ester was dissolved in 15 mL of freshly distilled acetonitrile, and then 2.09 mL (12 mmol, 1.55 g) of DIEA and 0.65 mL (8.6 mmol, 0.69 g) of MOMCl were added in sequence. The mixture was stirred at room temperature overnight. After the reaction was complete, 10 mL of water was added, and the mixture was extracted with EA. The organic phases were combined, washed with water, and then washed with anhydrous Na 2 SO 4 After drying, filtering and removing the solvent on a rotary evaporator, a yellow solid (0.54 g) was obtained.
[0152] MS: [M+H] + 299.
[0153] 5-Isopropyl-2,4-di(methoxymethoxy)benzoic acid (3-1f)
[0154] 0.4 g (1.3 mmol) of methyl 5-isopropyl-2,4-di(methoxymethoxy)benzoate was dissolved in 20 mL of MeOH, 11 mL of 2 M LiOH was added, and the mixture was stirred at room temperature for 24 h. After the reaction was completed, 20 mL of DCM was added, and the aqueous phase was separated and the pH value was adjusted to 3-4 with 0.87 M HAc, and extracted with EA. After the organic phases were combined, they were washed with saturated brine until neutral, and anhydrous Na 2 SO 4 After drying, filtering and removing the solvent on a rotary evaporator, a white solid (0.3 g) was obtained.
[0155] MS: [M+H] + 285.
[0156] (2R,4R)-1-(5-isopropyl-2,4-di(methoxymethoxy)benzoyl)-4-phenylpyrrolidine-2-carboxylic acid methyl ester (3-1g)
[0157] 1.16g (4.1mmol) of the compound 5-isopropyl-2,4-di(methoxymethoxy)benzoic acid, 1.53g (4.1mmol) of HATU and 3.2mL of DIEA were dissolved in 30mL of DCM, and then 0.96g (4.1mmol) of cis-4-phenyl-D-proline methyl ester hydrochloride (H) was added and stirred at room temperature overnight. After TLC detection of the reaction was complete, the mixture was washed with 25mL of sodium bicarbonate and 15mL of saturated brine. After drying with anhydrous sodium sulfate, 1.75g of a white solid (0-30% EA / Hex) was obtained by column chromatography.
[0158] MS: [M+H] + 472.
[0159] (2R,4R)-1-(5-isopropyl-2,4-di(methoxymethoxy)benzoyl)-4-phenylpyrrolidine-2-carboxylic acid (3-1h)
[0160] 1.70 g of (2R, 4R)-1-(5-cyano-2,4-di(methoxymethoxy)benzoyl)-4-phenylpyrrolidine-2-carboxylic acid methyl ester was dissolved in 30 mL of MeOH, and 15 mL of 2M LiOH was added. The mixture was stirred at room temperature overnight. After the reaction was completed, 100 mL of DCM was added. After separation, the pH value of the aqueous phase was adjusted to 3-4 with 0.87 M HAc, and extracted with EA. After the organic phases were combined, they were washed with saturated brine until neutral, and washed with anhydrous Na 2 SO 4 After drying and then filtering, the solvent was removed on a rotary evaporator to obtain 1.5 g of a white solid.
[0161] MS: [M+H] + 458.
[0162] Compound 37-90
[0163] Compound 3-1h (100 mg, 0.22 mmol), R 5 R 6 NH (0.22mmol) and triethylamine (0.33mmol) were dissolved in DCM (2mL), and HOBT (44.55mg, 0.33mmol) and EDC (63.26mg, 0.33mmol) were added to stir at room temperature and react overnight. The reaction solution was added to 20mL DCM and washed three times with water (20mL×3), the organic layer was separated and dried, and the crude product of compound 3-1-54i was obtained by spin drying. The crude product of compound 3-1-54i was dissolved in MeOH (2mL), and the corresponding EA.HCl was added, stirred at room temperature for about 30min, the solvent was removed by spin drying, and solid 37-90 was obtained by HPLC preparation (compound data is shown in the table below).
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171] Example 5
[0172] This embodiment provides an enzyme activity assay of a compound of formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof: a screening platform for human Hsp90α inhibitors is constructed, and the fluorescence polarization (FP) method is applied. The principle is to detect the change in molecular weight before and after the interaction between the fluorescently labeled small molecule and other molecules, and calculate the fluorescence polarization values in the horizontal and vertical directions for correlation analysis. If the binding equilibrium between the fluorescently labeled small molecule and the macromolecule is established, it moves slowly when excited, and the measured fluorescence polarization light value will increase. If the binding between the fluorescently labeled small molecule and the macromolecule is replaced by other ligands, its rotation and flipping speed in the free state will become faster, the emitted light will be depolarized relative to the excitation light plane, and the measured polarization light value will decrease, thereby calculating the polarization value of the sample (polarization value unit mP).
[0173] The fluorescent labeling small molecule used in the present invention is GM-BODIPY (synthesized according to the synthesis method described in BMCL, 2003, 13, 3975-3978). The reaction was carried out in a 384-well black board, and the reaction hydrophobic protein HFB buffer used was: 50 mM KCl, 5 mM MgCl 2 , 20 mM Na 2 MoO 4 , 0.01% NP40, 0.1mg / ml BGG, 2mM DTT, pH 7.3. The reaction system volume is 50ml, including 30nM Hsp90α, 5nM GM-BODIPY (geldanamycin) and the small molecule compound to be tested of the present invention (compounds 1-90 in Table 1) or DMSO (dimethyl sulfoxide), and the DMSO does not exceed 2‰. A blank control group and a 5nM GM-BODIPY negative control group were set up. Only HFB buffer was added to the blank control wells. The reaction was carried out at 4 degrees Celsius for 12-16 hours. The microplate reader was used for detection. The excitation wavelength of polarized light was 485 / 20nm, and the emission wavelength was 535 / 25nm. The mP value was measured. The inhibition rate was calculated using the following formula:
[0174] (no compound added mP - compound added mP) / (no compound added mP - negative control mP) x 100%
[0175] After calculating the inhibition rate of the compound at different concentrations, calculate the IC of the compound 50 .
[0176] The compound of formula I or its pharmaceutically acceptable salt, solvate or hydrate is determined by fluorescence polarization (FP) method, and the inhibition rate of the compound at different concentrations is calculated, thereby completing the determination of activity at the enzyme level.
[0177] Example 6
[0178] This example provides the binding Ki of the compound of formula I or its pharmaceutically acceptable salt, solvate or hydrate to Hsp90α protein:
[0179] Biotinylated Hsp90α was added to 1 mg / ml YiSi magnetic beads coated with streptavidin (Pharmacia, product number RPNQ0012; 219 pmol streptavidin / mg) in a binding solution (10 mM Tris-HCl, 5 mM MgCl). 2, pH 7.0) to a final concentration of 225 nM, and then [allyl-3H]-17-AAG (2000 cpm / pmol) was added to a final concentration of 2 μM. 50 μl of this suspension was mixed with 50 μl of the test compound of the present invention (compounds 1-90 in Table 1) in 0.1-50 μM binding solution. The reaction was carried out at room temperature for 2-4 hours on a 96-well assay plate, and the reaction intensity was recorded using a Wallac microbial scintillation counter. The experimental data were substituted into the competitive binding formula, Ki = I 50 / (1+[L] / K d ) to obtain the Ki value.
[0180] Through this example, the Ki value of the binding of the compound of formula I or its pharmaceutically acceptable salt, solvate or hydrate to the Hsp90α protein was obtained.
[0181] Example 7
[0182] This example provides a cell-level activity assay of a compound of formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof:
[0183] This embodiment provides the anticancer effect of the compound of formula I or its pharmaceutically acceptable salt, solvate or hydrate, based on the common tumor cell lines recommended by the National Cancer Institute of the United States (see Monks A Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. J. Natl. Cancer Inst. 1991 83: 757-766). The cell lines selected by the present invention include: HCT116, HT-29, MCF-7, MDA-MB-231, H460, A549, ovca3, SKOV-3, pc-3, Hela, U87, Hep G2, Vero, B16, SGC-7901, HL-60, JAK3STAT5, K562 / ADR, BEL7404, TE-1, ZR-75-30, H1 975, BT474, U266, K562, A375, Caki-1, SW620, MCF7, Molt-4, MDA-MB-435s, HO-8910.
[0184] The growth inhibition of tumor cells was detected by using Cell Counting Kit-8 (CCK-8) cytotoxicity screening experiment. Cell Counting Kit-8 (CCK-8) is a detection method based on WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolyl monosodium salt). The specific steps are as follows: The tumor cell suspension was inoculated into a 96-well cell culture plate at a concentration of 5000 / well and cultured for 24 hours (37°C, 5% CO 2 Different concentrations of the drug to be tested were added for 6-48 hours, and then CCK-8 solution was added and placed in an incubator (37°C, 5% CO 2 ) Incubate until color develops (1-4 hours), and measure the optical density (OD value) at a wavelength of 450nm with an enzyme marker. Record the results and calculate the inhibition rate of tumor cell growth of the compounds provided herein (compounds 1-90 in Table 1) at different concentrations and time. The inhibition rate of the drug on tumor cell growth is calculated according to the following formula: cell growth inhibition rate = (1-average OD value of the experimental group / average OD value of the control group) × 100%). The experiment was repeated 3 times.
[0185] This example shows the inhibitory rate of the compound of formula I or its pharmaceutically acceptable salt, solvate or hydrate on tumor cell growth. The compound of the present invention can effectively inhibit the growth of tumor cells.
[0186] Table 2 Protein binding and inhibitory activity of isopropyl series compounds
[0187]
[0188]
[0189] A: 0-200nM; B: 200-500nM; C: 500-1000nM; D: >1000nM. W: 0-0.5μM;
[0190] Results: During the design process, it was found that the introduction of chiral benzene rings in the compounds could enhance the binding ability of the compounds to HSP90 protein. The experimental results also showed that some of the newly designed and synthesized new series of compounds showed enhanced protein binding and ATPase inhibitory activity. In addition, compound 89 showed the strongest protein binding and inhibition and ATPase inhibitory activity.
[0191] Table 3 Protein binding and inhibitory activity of cyclopropyl series compounds
[0192]
[0193]
[0194] A: 0-200nM; B: 200-500nM; C: 500-1000nM; D: >1000nM. W: 0-0.5μM; X: 0.5–1μM; Y: 1-1.5μM; Z: >1.5μM. - indicates that its activity was not detected.
[0195] Results: The protein binding ability and ATPase inhibitory activity of the newly synthesized derivatives were increased by replacing the isopropyl group with a cyclopropyl group.
[0196] Table 4 Anti-tumor proliferation activity of isopropyl series compounds
[0197]
[0198] W:0-0.2μM; X:0.2–0.4μM; Y:0.4–0.6μM; Z:>0.6μM
[0199] Results: The cytotoxicity test of the derivatives with strong protein binding ability showed that the newly synthesized derivatives all showed significant cytotoxicity, especially to MCF-7 and A549 cell lines. In addition, derivative 89 had slightly stronger cytotoxicity than the positive control AT13387.
[0200] Table 5 Anti-tumor and anti-proliferative activity of cyclopropyl series compounds
[0201]
[0202]
[0203] W:0-0.2μM; X:0.2–0.4μM; Y:0.4–0.6μM; Z:>0.6μM
[0204] Results: The cytotoxicity experiments of the derivatives with strong protein binding ability showed that the newly synthesized derivatives all showed significant cytotoxicity, especially to MCF-7 and A549 cell lines. In addition, derivative 18 showed further enhanced cytotoxicity.
[0205] Table 6 Pharmacokinetic data of compounds 18 and 89 in rats
[0206]
[0207]
[0208] Results: The pharmacokinetic experiments of compounds 18 and 89 showed that both compounds exhibited good pharmacokinetic properties, especially Tmax and Cmax.
[0209] Table 7 Hsp90α selectivity relative to Grp94
[0210]
[0211] Results: The subtype selectivity experiments of compounds 18 and 89 showed that the selectivity of the newly designed synthetic compounds for Hsp90α subtypes was improved compared with AT13387. In addition, compared with previous studies (CN 102485720 B), the introduction of chiral phenyl groups greatly improved the subtype selectivity of the compounds for Hsp90α (compounds without chiral phenyl groups had no subtype selectivity).
[0212] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A compound, characterized in that The compound has the general structural formula shown in the following formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof: in: R1 is selected from H, alkyl, haloalkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, halogen, cyano, hydroxy, alkoxy, nitro, amino, monoalkylamino and dialkylamino; R2 is selected from -C(O)NR5R6, -S(O)NR3R4 and -S(O)2NR3R4; R3 and R4 are each independently selected from H, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl and substituted alkyl, wherein the cycloalkyl and heterocyclyl are optionally and independently substituted with substituents selected from alkyl, hydroxy, halogen and alkoxy, and wherein the substituent of the substituted alkyl is selected from hydroxy, amino, monoalkylamino, dialkylamino, alkylcarbonylamino, cycloalkyl, cycloalkylcarbonyl, aryl, heteroaryl, alkoxy, heterocyclyl and heterocyclylcarbonyl, The cycloalkyl and heterocyclic groups in the substituents of the substituted alkyl are optionally and independently substituted by substituents selected from alkyl, hydroxyl and alkoxy, The aryl or heteroaryl in the substituent of the substituted alkyl is optionally and independently substituted with a substituent selected from alkyl, haloalkyl, hydroxy, alkoxy, sulfamoyl, alkylsulfamoyl, alkylcarbonyl and halogen; or R3 and R4 together with the N atom to which they are attached form a heterocyclyl optionally containing additional heteroatoms, wherein the heterocyclyl is optionally and independently substituted with 1, 2 or 3 substituents selected from alkyl, hydroxy, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, heterocyclyl, aryl, arylalkyl, heteroaryl, alkoxyalkyl, alkylcarbonyl, alkylcarbonyloxy, aminoalkylcarbonyloxy, oxo, halogen, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, alkylcarbonylaminoalkyl, alkylcarbonylalkylaminoalkyl, amino, monoalkylamino and dialkylamino.
2. The compound according to claim 1, characterized in that The compound has the structure shown in the following formula IA:
3. The compound according to claim 1 or 2, characterized in that R1 is selected from H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, cyano, hydroxyl, C 1-6 Alkoxy, nitro, amino, single C 1-6 Alkylamino and di-C 1-6 Alkylamino; R2 is selected from -C(O)NR3R4 and -S(O)2NR3R4; R3 and R4 are each independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, 5-10 membered heteroaryl and substituted C 1-6 alkyl, Wherein C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl, halogen and C 1-6 The alkoxy substituent is substituted with wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the C 1-6 The C in the alkyl substituent 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 Substituents of the alkoxy group are substituted, The substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or R3 and R4 together with the N atom to which they are attached form a 3-8 membered heterocyclic group optionally containing 1, 2 or 3 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 Substitution of alkylamino groups; Furthermore, R1 is selected from H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, halogen, cyano, hydroxyl and C 1-6 Alkoxy; R2 is -C(O)NR3R4; R3 and R4 are each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl and substituted C 1-6 alkyl, Wherein C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 The alkoxy substituent is substituted with wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or R3 and R4 together with the N atom to which they are attached form a 3-8 membered heterocyclic group optionally containing 1 or 2 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
4. The compound according to claim 1 or 2, characterized in that R1 is selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl and cyano groups; R2 is -C(O)NR3R4; R3 and R4 are each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, C 2-6 Alkenyl and substituted C 1-6 alkyl, Wherein C 3-8 Cycloalkyl and 3-8 membered heterocyclyl are optionally and independently selected from C 1-6 Alkyl, hydroxyl and C 1-6 The alkoxy substituent is substituted with wherein the substituted C 1-6 The substituent of the alkyl group is selected from hydroxyl, amino, mono-C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-6 Alkylcarbonylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkylcarbonyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 alkoxy, 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from O, S and N, and heterocyclylcarbonyl, wherein the substituted C 1-6 The C in the alkyl substituent 6-10 Aryl and 5-10 membered heteroaryl are optionally and independently selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, sulfamoyl, C 1-6 Alkylsulfonyl, C 1-6 Alkylcarbonyl, halogen substituents; or R3 and R4 together with the N atom to which they are attached form a 3-8 membered heterocyclic group optionally containing 1 or 2 additional heteroatoms independently selected from O, S and N, wherein the 3-8 membered heterocyclic group is optionally and independently selected from C 1-6 Alkyl, hydroxyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 3-8 Cycloalkyl C 1-6 alkyloxy, a 3-8 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, S and N, C 6-10 Aryl, C 6-10 Arylalkyl, 5-10 membered heteroaryl, C 1-6 Epoxy C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, aminoC 1-6 Alkylcarbonyloxy, oxo, halogen, hydroxy 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl, C 1-6 Alkylcarbonylamino C 1-6 Alkyl, C 1-6 Alkylcarbonyl C 1-6 Alkylamino C 1-6 Alkyl, amino, single C 1-6 Alkylamino and di-C 1-6 The substituents of the alkylamino group are substituted.
5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises at least the compound according to any one of claims 1 to 4 and a pharmaceutically acceptable excipient, carrier or auxiliary material.
6. A selective heat shock protein 90 inhibitor, characterized in that: The selective heat shock protein 90 inhibitor comprises at least the compound according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5.
7. Use of the compound according to any one of claims 1 to 4, the pharmaceutical composition according to claim 5 or the selective heat shock protein 90 inhibitor according to claim 6 in any one or more of the following: (a) Selectively inhibit heat shock protein 90α; (b) inhibiting cancer cells or preparing products that inhibit cancer cells; (c) Preparation of products for the prevention and / or (adjuvant) treatment of cancer.
8. The use according to claim 7, characterized in that In (b), the cancer cells are selected from the following cancer cells: bladder cancer, breast cancer, cervical cancer, colon cancer (including colorectal cancer), esophageal cancer, head and neck cancer, liver cancer, lung cancer (including small cell lung cancer and non-small cell lung cancer), melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, sarcoma (including osteosarcoma), skin cancer (including squamous cell carcinoma), gastric cancer, testicular cancer, thyroid cancer and uterine cancer; In (c), the cancer is any one or more selected from bladder cancer, breast cancer, cervical cancer, colon cancer (including colorectal cancer), esophageal cancer, head and neck cancer, liver cancer, lung cancer (including small cell lung cancer and non-small cell lung cancer), melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, sarcoma (including osteosarcoma), skin cancer (including squamous cell carcinoma), gastric cancer, testicular cancer, thyroid cancer and uterine cancer.
9. A method for inhibiting cancer cells in vitro, characterized in that: The method comprises the step of using the compound according to any one of claims 1 to 4, the pharmaceutical composition according to claim 5, or the heat shock protein 90 inhibitor according to claim 6; Further, the cancer cells are selected from the following cancer cells: bladder cancer, breast cancer, cervical cancer, colon cancer (including colorectal cancer), esophageal cancer, head and neck cancer, liver cancer, lung cancer (including small cell lung cancer and non-small cell lung cancer), melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, sarcoma (including osteosarcoma), skin cancer (including squamous cell carcinoma), gastric cancer, testicular cancer, thyroid cancer and uterine cancer.
10. A method for inhibiting heat shock protein 90 in vitro, characterized in that: The method comprises the step of using the compound according to any one of claims 1 to 4, the pharmaceutical composition according to claim 5, or the heat shock protein 90 inhibitor according to claim 6; Furthermore, the heat shock protein 90 is heat shock protein 90α.
Citation Information
Patent Citations
Tetrahydroisoquinoline-3-carboxylic acid heat shock protein 90 inhibitor and application thereof
CN107311986A
Chiral macrocyclic compound as protein kinase inhibitor and application thereof
CN114763360A
Anti-proliferative compounds and uses thereof
WO2014011713A2
